Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical-stage oncology company completed $318M IPO in Jan 2026 — first biotech IPO of 2026 (Nasdaq: AKTS); Eli Lilly took $100M stake; developing alpha-emitting radiopharmaceutical AKY-1189 targeting Nectin-4 for bladder and other solid tumors.
Aktis Oncology is a Boston-based clinical-stage oncology company developing alpha-emitting radiopharmaceuticals against prevalent solid tumors. The company completed a $318 million IPO in January 2026 — the first significant biotech IPO of 2026 — pricing 17.65 million shares at $18 each on the Nasdaq under ticker AKTS. Eli Lilly stepped in to purchase $100 million of the offering.
CVS Health-operated pharmacy inside Target (NYSE: TGT) stores serving 100M weekly shoppers; $1.9B 2015 Target-to-CVS pharmacy acquisition creating store-within-store pharmacy integrated with Target Circle loyalty.
Target Pharmacy refers to the pharmacy services within Target Corporation's (NYSE: TGT) retail stores — providing prescription dispensing, immunizations, and health consultations to Target shoppers combining pharmacy errands with retail shopping. In 2015, Target sold its pharmacy and clinic operations to CVS Health (NYSE: CVS) for $1.9 billion, converting the in-store locations to CVS Pharmacy branding under a long-term licensing agreement — making what shoppers call "Target Pharmacy" operationally a CVS pharmacy located inside Target's 1,900+ US stores, operating under CVS management while Target shoppers earn Target Circle rewards on eligible pharmacy purchases.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.